TAXUS ATLAS: a multicenter, single-arm study of the TAXUS Liberte SR stent for the treatment of patients with de novo coronary artery lesions.

Trial Profile

TAXUS ATLAS: a multicenter, single-arm study of the TAXUS Liberte SR stent for the treatment of patients with de novo coronary artery lesions.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2012

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms TAXUS-ATLAS; TAXUS-ATLAS-Long-Lesion; TAXUS-ATLAS-Small-Vessel
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 01 Feb 2012 Additional trial investigator (Peter Maurer) and trial location (China, Taiwan) added as reported by ClinicalTrials.gov record.
    • 10 Nov 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 10 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top